Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX.

Sci Rep · 2021 · PMC8285533 · PMID 34272423

Europe PMC DOI

hedged sentence

0.0320

closest p · 0.6× alpha

0.0320

boldest claim

The sentences

marginal significanceP = 0.032actually significant

On the multivariate analysis, the G12D/V mutation was associated with a poor prognosis in both cohorts, with marginal significance (HR = 2.015, 95% CI = 1.064–3.817, P = 0.032 in the discovery cohort; HR = 2.366, 95% CI = 1.109–5.046, P = 0.026 in the validation cohort).

also in 5,069 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.